instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Uterine pseudoaneurysm on the basis of deep infiltrating endometriosis during pregnancy-a case report.
BACKGROUND
Pseudoaneurysm of the uterine artery (UPA) is a rare cause of potentially life-threatening hemorrhage during pregnancy and puerperium. It is an uncommon condition that mainly occurs after traumatic injury t... | AMOXICILLIN\CLAVULANIC ACID, MORPHINE | DrugsGivenReaction | CC BY | 33836672 | 19,291,924 | 2021-04-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exposure during pregnancy'. | Uterine pseudoaneurysm on the basis of deep infiltrating endometriosis during pregnancy-a case report.
BACKGROUND
Pseudoaneurysm of the uterine artery (UPA) is a rare cause of potentially life-threatening hemorrhage during pregnancy and puerperium. It is an uncommon condition that mainly occurs after traumatic injury t... | AMOXICILLIN\CLAVULANIC ACID, MORPHINE | DrugsGivenReaction | CC BY | 33836672 | 19,291,924 | 2021-04-09 |
What was the administration route of drug 'MORPHINE'? | Uterine pseudoaneurysm on the basis of deep infiltrating endometriosis during pregnancy-a case report.
BACKGROUND
Pseudoaneurysm of the uterine artery (UPA) is a rare cause of potentially life-threatening hemorrhage during pregnancy and puerperium. It is an uncommon condition that mainly occurs after traumatic injury t... | Oral | DrugAdministrationRoute | CC BY | 33836672 | 19,291,924 | 2021-04-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Contraindicated product administered'. | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | GLYBURIDE, INSULIN ASPART, INSULIN DETEMIR | DrugsGivenReaction | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoglycaemia'. | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | GLYBURIDE, INSULIN ASPART, INSULIN DETEMIR | DrugsGivenReaction | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Treatment failure'. | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | GLYBURIDE, INSULIN ASPART, INSULIN DETEMIR | DrugsGivenReaction | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Weight decreased'. | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | GLYBURIDE, INSULIN ASPART, INSULIN DETEMIR | DrugsGivenReaction | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
What is the weight of the patient? | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | 68 kg. | Weight | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
What was the administration route of drug 'GLYBURIDE'? | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | Oral | DrugAdministrationRoute | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
What was the dosage of drug 'INSULIN DETEMIR'? | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | FOUR UNITS | DrugDosageText | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
What was the outcome of reaction 'Hypoglycaemia'? | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | Recovering | ReactionOutcome | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
What was the outcome of reaction 'Weight decreased'? | Successful transition from insulin to sulfonylurea, on second attempt, in a 24-year-old female with neonatal diabetes secondary to KCNJ11 gene mutation.
Neonatal diabetes (NDM) is defined as diabetes that occurs in the first 6 months of life, the majority of cases are due to sporadic mutations. ATP-sensitive potassium ... | Recovering | ReactionOutcome | CC BY-NC | 33837025 | 19,512,330 | 2021-04-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Actinic keratosis'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | ASPIRIN, CLADRIBINE, SODIUM PROPIONATE, VALPROIC ACID | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 19,174,692 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute kidney injury'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | AMLODIPINE BESYLATE, CLADRIBINE, DALFAMPRIDINE | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cutaneous vasculitis'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | AMITRIPTYLINE, APIXABAN, BACLOFEN, CHOLECALCIFEROL, CLADRIBINE, DESOGESTREL, INSULIN LISPRO, LEVOTHYROXINE, MODAFINIL, PROPIVERINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 19,174,773 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Glomerulonephritis'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | AMLODIPINE BESYLATE, CLADRIBINE, DALFAMPRIDINE | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyperkeratosis'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | CLADRIBINE | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukoplakia'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | CLADRIBINE | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lymphocyte count decreased'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | CLADRIBINE | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Squamous cell carcinoma'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | ASPIRIN, CLADRIBINE, SODIUM PROPIONATE, VALPROIC ACID | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 19,174,692 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'White blood cell count decreased'. | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | CLADRIBINE | DrugsGivenReaction | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
What was the administration route of drug 'AMLODIPINE BESYLATE'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
What was the administration route of drug 'CLADRIBINE'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
What was the administration route of drug 'DALFAMPRIDINE'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
What was the dosage of drug 'AMLODIPINE BESYLATE'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | 5 mg (milligrams). | DrugDosage | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
What was the dosage of drug 'ASPIRIN'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | 100 mg (milligrams). | DrugDosage | CC BY-NC-ND | 33837059 | 19,174,692 | 2021-05 |
What was the dosage of drug 'CHOLECALCIFEROL'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | 1000 IE (1?0?0) | DrugDosageText | CC BY-NC-ND | 33837059 | 19,174,773 | 2021-05 |
What was the dosage of drug 'DALFAMPRIDINE'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | 10 mg (milligrams). | DrugDosage | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
What was the dosage of drug 'INSULIN LISPRO'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | NACH BZ INSULIN GLARGIN 30 IE ABENDS (AS REPORTED) | DrugDosageText | CC BY-NC-ND | 33837059 | 19,174,773 | 2021-05 |
What was the dosage of drug 'VALPROIC ACID'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | 300 mg (milligrams). | DrugDosage | CC BY-NC-ND | 33837059 | 19,174,692 | 2021-05 |
What was the outcome of reaction 'Actinic keratosis'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 19,174,692 | 2021-05 |
What was the outcome of reaction 'Acute kidney injury'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovered with sequelae (consequent health issues) | ReactionOutcome | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
What was the outcome of reaction 'Cutaneous vasculitis'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 19,174,773 | 2021-05 |
What was the outcome of reaction 'Glomerulonephritis'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Not recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
What was the outcome of reaction 'Hyperkeratosis'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
What was the outcome of reaction 'Leukoplakia'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
What was the outcome of reaction 'Lymphocyte count decreased'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovering | ReactionOutcome | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
What was the outcome of reaction 'Lymphopenia'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 18,633,699 | 2021-05 |
What was the outcome of reaction 'Squamous cell carcinoma'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 19,174,692 | 2021-05 |
What was the outcome of reaction 'White blood cell count decreased'? | Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment.
To report 77 patients with multiple sclerosis (MS) who developed skin-related adverse events (AEs) following treatment with cladribine.
We evaluated our prospective bicentric cladribine cohort. Cladribine-treated patients with a skin ... | Recovered | ReactionOutcome | CC BY-NC-ND | 33837059 | 16,197,216 | 2021-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abortion induced'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838757 | 20,026,589 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse reaction'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838757 | 20,026,602 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838757 | 20,026,602 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Exposure during pregnancy'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838757 | 19,459,492 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Foetal exposure during pregnancy'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LAMOTRIGINE | DrugsGivenReaction | CC BY | 33838757 | 19,179,797 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Foetal malformation'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LAMOTRIGINE | DrugsGivenReaction | CC BY | 33838757 | 19,179,797 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure before pregnancy'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838757 | 20,026,589 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure during pregnancy'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838757 | 20,026,589 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stevens-Johnson syndrome'. | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838757 | 20,026,602 | 2021-04-10 |
What was the administration route of drug 'LEVETIRACETAM'? | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | Oral | DrugAdministrationRoute | CC BY | 33838757 | 20,026,589 | 2021-04-10 |
What was the outcome of reaction 'Adverse event'? | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | Fatal | ReactionOutcome | CC BY | 33838757 | 19,459,445 | 2021-04-10 |
What was the outcome of reaction 'Death'? | The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Levetiracetam and zonisamide are licensed as monotherapy for patients with focal epilepsy, bu... | Fatal | ReactionOutcome | CC BY | 33838757 | 20,026,602 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abortion spontaneous'. | The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Valproate is a first-line treatment for patients with newly diagnosed idiopathi... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838758 | 20,026,588 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse event'. | The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Valproate is a first-line treatment for patients with newly diagnosed idiopathi... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838758 | 20,026,683 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Congenital anomaly'. | The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Valproate is a first-line treatment for patients with newly diagnosed idiopathi... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838758 | 20,026,014 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Low birth weight baby'. | The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Valproate is a first-line treatment for patients with newly diagnosed idiopathi... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838758 | 20,026,014 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure before pregnancy'. | The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Valproate is a first-line treatment for patients with newly diagnosed idiopathi... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838758 | 20,026,014 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure during pregnancy'. | The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Valproate is a first-line treatment for patients with newly diagnosed idiopathi... | LEVETIRACETAM | DrugsGivenReaction | CC BY | 33838758 | 20,026,014 | 2021-04-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | AMOXICILLIN, CEFOTAXIME SODIUM, GENTAMICIN, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33840247 | 20,110,423 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemolysis'. | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | AMOXICILLIN, CEFOTAXIME SODIUM, GENTAMICIN, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33840247 | 20,110,423 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | AMOXICILLIN, CEFOTAXIME SODIUM, GENTAMICIN, METRONIDAZOLE | DrugsGivenReaction | CC BY-NC | 33840247 | 20,110,423 | 2021-04 |
What was the administration route of drug 'CEFOTAXIME SODIUM'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 33840247 | 20,133,927 | 2021-04 |
What was the administration route of drug 'GENTAMICIN'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 33840247 | 20,133,927 | 2021-04 |
What was the administration route of drug 'METRONIDAZOLE'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 33840247 | 20,133,927 | 2021-04 |
What was the dosage of drug 'AMOXICILLIN'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | PREOPERATIVE | DrugDosageText | CC BY-NC | 33840247 | 20,110,423 | 2021-04 |
What was the dosage of drug 'PIPERACILLIN SODIUM\TAZOBACTAM SODIUM'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | UNK, THERAPY WAS CONTINUED FOR A TOTAL OF 7 DAYS | DrugDosageText | CC BY-NC | 33840247 | 20,133,927 | 2021-04 |
What was the outcome of reaction 'Anaemia'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | Recovered | ReactionOutcome | CC BY-NC | 33840247 | 20,110,423 | 2021-04 |
What was the outcome of reaction 'Haemolysis'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | Recovered | ReactionOutcome | CC BY-NC | 33840247 | 20,110,423 | 2021-04 |
What was the outcome of reaction 'Thrombocytopenia'? | Hemolytic uremic syndrome following complicated appendicitis in a child: what is the missing link?
We herein describe an 18-month-old boy who underwent initially successful surgical and antibiotic treatment of complicated appendicitis with postoperative occurrence of hemolytic uremic syndrome (HUS). This complication w... | Recovered | ReactionOutcome | CC BY-NC | 33840247 | 20,110,423 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemorrhage intracranial'. | Mechanical thrombectomy in acute ischaemic stroke patients with pre-interventional intracranial haemorrhage following intravenous thrombolysis.
BACKGROUND
Data on outcome of endovascular treatment in patients with acute ischaemic stroke due to large vessel occlusion suffering from intravenous thrombolysis-associated in... | ASPIRIN, CLOPIDOGREL BISULFATE, TIROFIBAN | DrugsGivenReaction | CC BY | 33840277 | 20,138,675 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Labelled drug-drug interaction medication error'. | Mechanical thrombectomy in acute ischaemic stroke patients with pre-interventional intracranial haemorrhage following intravenous thrombolysis.
BACKGROUND
Data on outcome of endovascular treatment in patients with acute ischaemic stroke due to large vessel occlusion suffering from intravenous thrombolysis-associated in... | ASPIRIN, CLOPIDOGREL BISULFATE, TIROFIBAN | DrugsGivenReaction | CC BY | 33840277 | 20,138,675 | 2021-10 |
What was the outcome of reaction 'Haemorrhage intracranial'? | Mechanical thrombectomy in acute ischaemic stroke patients with pre-interventional intracranial haemorrhage following intravenous thrombolysis.
BACKGROUND
Data on outcome of endovascular treatment in patients with acute ischaemic stroke due to large vessel occlusion suffering from intravenous thrombolysis-associated in... | Fatal | ReactionOutcome | CC BY | 33840277 | 20,138,675 | 2021-10 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular car... | ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 33840693 | 19,258,865 | 2021-10-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular car... | ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 33840693 | 19,258,865 | 2021-10-15 |
What was the dosage of drug 'ATEZOLIZUMAB'? | Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular car... | UNK, CYCLIC | DrugDosageText | CC BY-NC-ND | 33840693 | 19,258,865 | 2021-10-15 |
What was the dosage of drug 'BEVACIZUMAB'? | Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular car... | UNK, CYCLIC | DrugDosageText | CC BY-NC-ND | 33840693 | 19,258,865 | 2021-10-15 |
What was the dosage of drug 'CARBOPLATIN'? | Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular car... | UNK, CYCLIC | DrugDosageText | CC BY-NC-ND | 33840693 | 19,258,865 | 2021-10-15 |
What was the dosage of drug 'PACLITAXEL'? | Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Chemotherapy for multiple primary malignancies is challenging. We herein report a case of synchronous primary lung adenocarcinoma and hepatocellular car... | UNK, CYCLIC | DrugDosageText | CC BY-NC-ND | 33840693 | 19,258,865 | 2021-10-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune reconstitution inflammatory syndrome'. | Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient.
A 94-year-old woman with rheumatoid arthritis who had been treated with low-dose methotrexate was referred to our hospital because of a 3-day histo... | LEVOLEUCOVORIN, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33840694 | 19,232,822 | 2021-10-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancytopenia'. | Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient.
A 94-year-old woman with rheumatoid arthritis who had been treated with low-dose methotrexate was referred to our hospital because of a 3-day histo... | LEVOLEUCOVORIN, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33840694 | 19,232,822 | 2021-10-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumocystis jirovecii pneumonia'. | Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient.
A 94-year-old woman with rheumatoid arthritis who had been treated with low-dose methotrexate was referred to our hospital because of a 3-day histo... | LEVOLEUCOVORIN, METHOTREXATE | DrugsGivenReaction | CC BY-NC-ND | 33840694 | 19,232,822 | 2021-10-01 |
What was the administration route of drug 'METHOTREXATE'? | Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient.
A 94-year-old woman with rheumatoid arthritis who had been treated with low-dose methotrexate was referred to our hospital because of a 3-day histo... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33840694 | 19,232,822 | 2021-10-01 |
What was the outcome of reaction 'Immune reconstitution inflammatory syndrome'? | Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient.
A 94-year-old woman with rheumatoid arthritis who had been treated with low-dose methotrexate was referred to our hospital because of a 3-day histo... | Recovering | ReactionOutcome | CC BY-NC-ND | 33840694 | 19,232,822 | 2021-10-01 |
What was the outcome of reaction 'Pancytopenia'? | Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient.
A 94-year-old woman with rheumatoid arthritis who had been treated with low-dose methotrexate was referred to our hospital because of a 3-day histo... | Recovering | ReactionOutcome | CC BY-NC-ND | 33840694 | 19,232,822 | 2021-10-01 |
What was the outcome of reaction 'Pneumocystis jirovecii pneumonia'? | Immune Reconstitution Inflammatory Syndrome-like Condition Associated with Pneumocystis jirovecii Pneumonia During Folinic Acid Treatment in a Rheumatoid Arthritis Patient.
A 94-year-old woman with rheumatoid arthritis who had been treated with low-dose methotrexate was referred to our hospital because of a 3-day histo... | Recovering | ReactionOutcome | CC BY-NC-ND | 33840694 | 19,232,822 | 2021-10-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Steroid diabetes'. | PaO2-guided Low-dose Oxygen Therapy for Pneumatosis Cystoides Intestinalis to Prevent Acute Exacerbation of Interstitial Pneumonia.
We herein report the first case of low-dose oxygen therapy for pneumatosis cystoides intestinalis (PCI) using PaO2 as a therapeutic index to prevent acute exacerbation of interstitial pneu... | PREDNISOLONE | DrugsGivenReaction | CC BY-NC-ND | 33840698 | 20,036,050 | 2021-10-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arterial intramural haematoma'. | Delayed Endovascular Thrombectomy for Ischemic Stroke in a Young Woman with No Known Risk Factors: A Case Report.
BACKGROUND National guidelines and consensus statements suggest a 24-hour window for endovascular recanalization in patients presenting with acute ischemic stroke due to large-vessel occlusion. However, the... | ASPIRIN | DrugsGivenReaction | CC BY-NC-ND | 33840809 | 19,391,040 | 2021-04-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Concomitant disease aggravated'. | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | TREPROSTINIL | DrugsGivenReaction | CC BY-NC-ND | 33841939 | 19,326,144 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | EPOPROSTENOL SODIUM, OXYGEN | DrugsGivenReaction | CC BY-NC-ND | 33841939 | 19,180,598 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | EPOPROSTENOL | DrugsGivenReaction | CC BY-NC-ND | 33841939 | 19,401,846 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoxia'. | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | TREPROSTINIL | DrugsGivenReaction | CC BY-NC-ND | 33841939 | 19,326,144 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lung transplant'. | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | EPOPROSTENOL SODIUM, OXYGEN | DrugsGivenReaction | CC BY-NC-ND | 33841939 | 19,180,562 | 2021-03 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy non-responder'. | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | TREPROSTINIL | DrugsGivenReaction | CC BY-NC-ND | 33841939 | 19,326,144 | 2021-03 |
What was the administration route of drug 'EPOPROSTENOL SODIUM'? | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33841939 | 19,180,598 | 2021-03 |
What was the administration route of drug 'EPOPROSTENOL'? | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33841939 | 19,401,846 | 2021-03 |
What was the administration route of drug 'OXYGEN'? | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33841939 | 19,180,598 | 2021-03 |
What was the administration route of drug 'TREPROSTINIL'? | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | Subcutaneous | DrugAdministrationRoute | CC BY-NC-ND | 33841939 | 19,326,144 | 2021-03 |
What was the dosage of drug 'EPOPROSTENOL'? | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | 10 NG/KG/MIN | DrugDosageText | CC BY-NC-ND | 33841939 | 19,401,846 | 2021-03 |
What was the dosage of drug 'TREPROSTINIL'? | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | 15.5 NG/KG/MIN | DrugDosageText | CC BY-NC-ND | 33841939 | 19,326,144 | 2021-03 |
What was the outcome of reaction 'Death'? | Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction.
Group 3 pulmonary hypertension (PH) is a common complication in patients with lung diseases but there are currently no FDA-approved therapies. The data is conflicting, but a few small studies suggest potential benefits ... | Fatal | ReactionOutcome | CC BY-NC-ND | 33841939 | 19,180,598 | 2021-03 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.